Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating reaffirmed by research analysts at Commerzbank AG in a research report issued on Friday.

A number of other research analysts have also commented on the company. Deutsche Bank AG reissued a “buy” rating on shares of Qiagen NV in a report on Monday, June 6th. Zacks Investment Research raised Qiagen NV from a “sell” rating to a “hold” rating in a report on Monday, July 4th. HSBC raised Qiagen NV from a “hold” rating to a “buy” rating in a report on Monday, August 1st. Morgan Stanley reaffirmed a “buy” rating on shares of Qiagen NV in a report on Wednesday, June 8th. Finally, TheStreet raised Qiagen NV from a “hold” rating to a “buy” rating in a report on Friday, July 29th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Qiagen NV has a consensus rating of “Buy” and a consensus target price of $25.36.

Shares of Qiagen NV (NASDAQ:QGEN) opened at 26.16 on Friday. The firm has a 50-day moving average price of $26.78 and a 200 day moving average price of $23.32. Qiagen NV has a 12 month low of $19.94 and a 12 month high of $28.04. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of 52.32 and a beta of 0.90.

Qiagen NV (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.01. The business had revenue of $334.40 million for the quarter, compared to analyst estimates of $326.73 million. Qiagen NV had a return on equity of 9.21% and a net margin of 9.13%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 EPS. On average, analysts anticipate that Qiagen NV will post $1.09 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of QGEN. Franklin Resources Inc. increased its position in Qiagen NV by 0.5% in the second quarter. Franklin Resources Inc. now owns 26,190,642 shares of the company’s stock valued at $566,914,000 after buying an additional 125,887 shares during the period. Manning & Napier Advisors LLC increased its position in Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock valued at $133,287,000 after buying an additional 1,470,315 shares during the period. Vanguard Group Inc. increased its position in Qiagen NV by 0.6% in the second quarter. Vanguard Group Inc. now owns 5,287,123 shares of the company’s stock valued at $115,312,000 after buying an additional 29,628 shares during the period. BlackRock Fund Advisors increased its position in Qiagen NV by 6.7% in the first quarter. BlackRock Fund Advisors now owns 5,062,893 shares of the company’s stock valued at $113,105,000 after buying an additional 318,905 shares during the period. Finally, Harris Associates L P increased its position in Qiagen NV by 62.6% in the second quarter. Harris Associates L P now owns 3,331,940 shares of the company’s stock valued at $72,670,000 after buying an additional 1,282,240 shares during the period. Institutional investors and hedge funds own 58.78% of the company’s stock.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with Analyst Ratings Network's FREE daily email newsletter.